<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707196</url>
  </required_header>
  <id_info>
    <org_study_id>17782</org_study_id>
    <secondary_id>I3Y-IN-JPEC</secondary_id>
    <nct_id>NCT04707196</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib in Indian Women With Advanced Breast Cancer</brief_title>
  <official_title>A Single-Arm, Phase 4 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, in Combination With Endocrine Therapy (Anastrozole/Letrozole or Fulvestrant) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced and/or Metastatic Breast Cancer in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety and tolerability of&#xD;
      abemaciclib when given in combination with hormone therapy in Indian women with advanced&#xD;
      breast cancer. Participants must have hormone receptor positive (HR+), human epidermal growth&#xD;
      factor receptor 2 negative (HER2-) breast cancer and must live in India. For each&#xD;
      participant, the study could last up to eight months and may include up to eight visits to&#xD;
      the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">August 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Discontinue from Study Treatment Due to Adverse Events</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Percentage of Participants who Discontinue from Study Treatment Due to Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Abemaciclib + NSAI or Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally or Fulvestrant administered intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + NSAI or Fulvestrant</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nonsteroidal Aromatase Inhibitor (NSAI)</intervention_name>
    <description>Letrozole administered orally or anastrozole administered orally (physician choice)</description>
    <arm_group_label>Abemaciclib + NSAI or Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Administered intramuscularly</description>
    <arm_group_label>Abemaciclib + NSAI or Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor&#xD;
             receptor 2-negative (HER2-) breast cancer&#xD;
&#xD;
          -  Have locoregionally recurrent disease not amenable to resection or radiation therapy&#xD;
             with curative intent or metastatic disease&#xD;
&#xD;
          -  Have postmenopausal status&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             scale&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  Have discontinued previous cytotoxic therapies, biological agents, investigational&#xD;
             agents, and radiotherapy&#xD;
&#xD;
          -  Are able to swallow oral formulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis.&#xD;
&#xD;
          -  Have clinical evidence or history of central nervous system metastasis.&#xD;
&#xD;
          -  Have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant&#xD;
             chemotherapy), fulvestrant, everolimus, or any cyclin-dependent kinase (CDK) 4 &amp; 6&#xD;
             inhibitor.&#xD;
&#xD;
          -  Have received recent (within 28 days prior to study intervention) live vaccination&#xD;
             (for example, yellow fever). Seasonal flu vaccinations that do not contain a live&#xD;
             virus are permitted.&#xD;
&#xD;
          -  Have a personal history of presyncope or syncope of either unexplained or&#xD;
             cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden&#xD;
             cardiac arrest.&#xD;
&#xD;
          -  Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma&#xD;
             skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no&#xD;
             therapy for a minimum of 3 years.&#xD;
&#xD;
          -  Have received an autologous or allogeneic stem-cell transplant&#xD;
&#xD;
          -  Have clinically relevant active bacterial or fungal infection, or detectable viral&#xD;
             infection (for example, human immunodeficiency virus or viral hepatitis). Screening is&#xD;
             not required for enrolment.&#xD;
&#xD;
          -  Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MNJ Institute of Oncology</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9848792682</phone>
    </contact>
    <investigator>
      <last_name>Parimkayala Radhika</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Private Limited</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9727053929</phone>
    </contact>
    <investigator>
      <last_name>Dhruv Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unique Hospital Multispecialty &amp; Research Institute</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>91- 9909918887</phone>
    </contact>
    <investigator>
      <last_name>Tanveer Maksud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anand Multispeciality Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9879794949</phone>
    </contact>
    <investigator>
      <last_name>Jigar Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital &amp; Research Centre (KCHRC)</name>
      <address>
        <city>Waghodia</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>02668265396</phone>
    </contact>
    <investigator>
      <last_name>Niraj Bhat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCG Cancer Centre, Kalinga Rao Road</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9242698750</phone>
    </contact>
    <investigator>
      <last_name>Satheesh CT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9447134973</phone>
    </contact>
    <investigator>
      <last_name>Anoop T Manoharan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRJ-CBCC Cancer Hospital</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9009779517</phone>
    </contact>
    <investigator>
      <last_name>Rakesh Taran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingsway Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7066580511</phone>
    </contact>
    <investigator>
      <last_name>Saurabh Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meditrina Institute of Medical Sciences</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7126669602</phone>
    </contact>
    <investigator>
      <last_name>SMITA GUPTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCG Manavata Cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919823061929</phone>
    </contact>
    <investigator>
      <last_name>Rajnish V Nagarkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic and Grant Medical Foundation</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9823133390</phone>
    </contact>
    <investigator>
      <last_name>Minish Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals Kolkata</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9674311610</phone>
    </contact>
    <investigator>
      <last_name>Prabrajya N Mohapatra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max Superspeciality Hospital</name>
      <address>
        <city>Chandigarh</city>
        <zip>160055</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8968839911</phone>
    </contact>
    <investigator>
      <last_name>Sachin Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute &amp; Research Center</name>
      <address>
        <city>Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>011-47022428</phone>
    </contact>
    <investigator>
      <last_name>D.C. Doval</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

